Table 3.

Adverse events during follow-up.

Type of adverse event	n (%)
Any adverse event	35 (12.1)
Skin reaction	12 (4.1)
Respiratory tract infection	8 (2.8)
Arthralgia	6 (2.1)
COVID-19 infection	3 (1.0)
Hair loss	2 (0.7)
Nasopharyngitis	1 (0.4)
Headache	1 (0.4)
Acute diverticulitis treated conservatively	1 (0.4)
Campylobacter gastroenteritis	1 (0.4)
Salmonella gastroenteritis	1 (0.4)
Persistent cough	1 (0.4)
Adverse events leading to drug withdrawal n = 9
Respiratory tract infection needing admission	2 (0.7)
Arthralgia	1 (0.4)
Skin reaction	3 (1.0)
Skin reaction and headache	1 (0.4)
Skin reaction and arthralgia	1 (0.4)
Persistent cough	1 (0.4)